Expanding Clinical Use of PSMA PET in Advanced Prostate Cancer

In ‘Expanding Clinical Use of PSMA PET in Advanced Prostate Cancer,’ our experts delve into how PSMA PET imaging is being incorporated into treatment decisions for patients with advanced and metastatic prostate cancer. While initially used primarily for staging and evaluating candidacy for radioligand therapy, PSMA PET is increasingly being applied to assess treatment response and disease progression across advanced prostate cancer. The panelists highlight the inclusion of PSMA PET in Prostate Cancer Working Group 4 criteria, marking a significant shift toward integrating PET findings into response assessment frameworks. Clinicians emphasize the importance of identifying new lesions rather than relying solely on changes in uptake intensity, aligning interpretation more closely with principles used in bone scan evaluation. The conversation also addresses how real-world use may extend beyond current FDA labeling and guideline language, particularly as evidence accumulates supporting broader clinical utility.

Our next episode, ‘Clinical Considerations for PSMA PET Agents in Advanced Prostate Cancer,’ outlines FDA-approved PSMA PET agents, their shared indications, and key practical considerations in clinical use. It highlights differences in urinary excretion and physiologic uptake that may affect scan interpretation, particularly in post-prostatectomy patients with low PSA recurrence.